Jim Cramer on Moderna (MRNA): “I’ve Been Against This Stock For So Long”
We recently published a list of Jim Cramer Talked About These 13 Stocks. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other stocks that Jim Cramer discusses.
A caller asked what Cramer thought of Moderna, Inc. (NASDAQ:MRNA), and he said:
“There’s gotta be some value in Moderna. There just has to be, but I’ve been against this stock for so long. I first discovered it at 18. Maybe that should be the price target.”
A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine.
Moderna (NASDAQ:MRNA) is a biotech company focused on creating vaccines and treatments using messenger RNA technology. The company works on solutions for various diseases. On March 26, highlighting the stock’s decline, Cramer said:
“Now, let’s consider the other side of the trade, the biggest losers, all of which were somehow connected to the data center except Moderna, which plunged 7% because of Financial Time’s story. It says they might… be targeted by RFK Junior at Health and Human Services and it’s certainly possible.”
Overall, MRNA ranks 3rd on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRNA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires
Disclosure: None. This article is originally published at Insider Monkey.
Content Original Link:
" target="_blank">
